The Trump administration on Tuesday scrambled to justify its decision to purchase millions of vaccines for the Pfizer-developed Covit-19 vaccine, which appeared to be the first to be approved for use in the United States. The Government Regulatory Authority for Food and Drug Administration (FDA) on Tuesday announced favorable preliminary findings from a review of Pfizer data, following approval for use in the UK and the first approved vaccine there. The Trump administration struck a deal for the 100m size of the Pfizer vaccine candidate last spring, but the administration turned down the offer to set aside additional levels, current Pfizer board member and former FDA commissioner Scott Courtleaf confirmed Tuesday. “Pfizer provided an additional exit from the program, basically a second-quarter allocation. We know the vaccine will be effective after the US government releases several interim reports,” Godlip told CNBC. I think they are betting that more than one vaccine is going to be approved and that there will be more vaccines on the market, which is why they did not take that extra 100m optional contract. “Following successful test results and approval in the United Kingdom due to growing global demand for its vaccine, the New York-based Pfizer cannot guarantee additional doses to the United States before next June,” the New York Times reported. It is not clear to what extent the vaccine attempt in the United States is a barrier to the decision not to get too much of the Pfizer vaccine. The news comes as more than 15 million corona virus cases have been reported worldwide, with a second vaccine candidate currently undergoing emergency approval from the FDA, and many additional vaccine candidates – some of which are easier to manage than the Pfizer vaccine, should be stored at a much colder temperature – final in the medical review Are on stage.But Donald True MP. And officials involved in the vaccine development program on Tuesday shattered the notion that the government had failed to prioritize the adequate supply of a vaccine produced by a US-based company. US-based Pfizer Coalition and its German pharmaceutical partner Bioendech are on track to get the first vaccine approved in the United States. To celebrate the good news of the vaccine and to say his part in it, Trump planned to hold an event at the White House on Tuesday called the “Vaccine Summit.” He planned to issue an executive order to prioritize vaccine exports to “Americans ahead of other countries,” but analysts said the order did not appear to have the same impact or effect as Trump’s other headline-grabbing orders. Operation Warp Speed, which is in charge of the government’s vaccine development program, Manshef Slavy, in charge of the government’s vaccine development program, told ABC’s Good Morning America on Tuesday: “Obviously, I don’t know.” Health officials named after President-elect Joe Biden, who will lead the vaccine rolling effort after taking office next month, have not been invited to the White House event, underscoring the risks of a continuing shortfall in the effort. State News reports that Trump was invited to the White House by executives of two more drug companies, Pfizer and Moderna – and its own vaccine candidate – for FDA approval. Slavy backed management’s decision not to buy the Pfizer vaccine in large quantities, saying on ABC they were looking at a variety of vaccines when there was an option to lock in additional Pfizer vaccine doses in the summer. “No one buys a reasonably high price from any vaccine because we don’t know what works, it’s better than any other,” Slavy said. Before taking over his current position, Sloy resigned from the Modern Board. The US government has also signed up for the 100m dose of Moderna vaccine. Both vaccines require two doses per patient, although a preliminary report on the Pfizer vaccine issued by the FDA on Tuesday found some safety after one dose. The report expedited the path to approval, with “no specific security concerns identified” preventing the provision of emergency use. “It simply came to our notice then [Pfizer] It has provided sufficient information to confirm the quality and sustainability of the vaccine for product approval under an EU, ”the report said. A spokesman for the Department of Health and Human Services told the Times that in addition to Pfizer and Moderna, the government has signed contracts for doses of vaccines for candidates who have not yet reached the stage of regulatory approval. “We hope to have 100 million doses of Pfizer vaccine as agreed in our contract, and beyond that we have five vaccine candidates, including 100 million doses on the way from Moderna,” he said.
Source